DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,467,268 | +3.7% | 5,914 | +0.3% | 0.07% | +4.2% |
| Q2 2023 | $1,415,497 | -7.1% | 5,898 | -2.4% | 0.07% | -17.4% |
| Q1 2023 | $1,523,477 | -1.7% | 6,045 | +3.5% | 0.09% | -7.5% |
| Q4 2022 | $1,549,878 | +3.1% | 5,839 | +0.2% | 0.09% | +5.7% |
| Q3 2022 | $1,504,000 | +2.4% | 5,825 | +0.5% | 0.09% | +3.5% |
| Q2 2022 | $1,469,000 | -20.9% | 5,795 | -8.4% | 0.08% | -1.2% |
| Q1 2022 | $1,856,000 | -5.2% | 6,326 | +6.4% | 0.09% | -6.5% |
| Q4 2021 | $1,957,000 | +11.6% | 5,947 | +3.2% | 0.09% | +1.1% |
| Q3 2021 | $1,754,000 | +12.3% | 5,762 | -1.0% | 0.09% | +13.8% |
| Q2 2021 | $1,562,000 | +35.7% | 5,820 | +13.8% | 0.08% | +17.6% |
| Q1 2021 | $1,151,000 | -1.0% | 5,115 | -2.3% | 0.07% | -5.6% |
| Q4 2020 | $1,163,000 | +2.9% | 5,235 | -0.3% | 0.07% | -7.7% |
| Q3 2020 | $1,130,000 | +23.9% | 5,250 | +1.8% | 0.08% | +5.4% |
| Q2 2020 | $912,000 | +21.4% | 5,157 | -4.9% | 0.07% | -6.3% |
| Q1 2020 | $751,000 | +2.5% | 5,424 | +13.6% | 0.08% | 0.0% |
| Q4 2019 | $733,000 | +18.0% | 4,773 | +11.0% | 0.08% | +8.2% |
| Q3 2019 | $621,000 | -6.8% | 4,301 | -7.7% | 0.07% | -6.4% |
| Q2 2019 | $666,000 | +13.1% | 4,660 | +4.5% | 0.08% | +9.9% |
| Q1 2019 | $589,000 | +21.9% | 4,458 | -4.7% | 0.07% | +1.4% |
| Q4 2018 | $483,000 | -4.4% | 4,680 | +0.8% | 0.07% | +12.9% |
| Q3 2018 | $505,000 | +10.3% | 4,645 | +0.2% | 0.06% | +5.1% |
| Q2 2018 | $458,000 | -3.4% | 4,638 | -4.2% | 0.06% | -9.2% |
| Q1 2018 | $474,000 | -2.1% | 4,840 | -7.1% | 0.06% | +10.2% |
| Q4 2017 | $484,000 | +8.8% | 5,211 | +0.5% | 0.06% | +3.5% |
| Q3 2017 | $445,000 | +2.3% | 5,186 | +0.5% | 0.06% | -6.6% |
| Q2 2017 | $435,000 | -0.9% | 5,159 | +0.4% | 0.06% | -42.5% |
| Q1 2017 | $439,000 | -99.8% | 5,138 | +97.0% | 0.11% | +221.2% |
| Q3 2016 | $204,441,000 | -0.6% | 2,608 | +20.2% | 0.03% | -13.2% |
| Q1 2016 | $205,751,000 | +99296.6% | 2,169 | -10.5% | 0.04% | -19.1% |
| Q2 2015 | $207,000 | – | 2,423 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |